Founded in March 2001 by a group of senior scientists returned from the United States, Chipscreen Biosciences focuses on developing innovative drugs with new mechanisms of action (MOA) for the treatment of human diseases in five major therapeutic areas, including cancer, metabolic diseases, autoimmune disorders, central nervous system disorders and antivirals, so as to provide patients with affordable, efficacious drugs to meet their clinical needs.
Chipscreen Biosciences was the first biotech firm approved for listing on the Shanghai Stock Exchange Science and Technology Innovation Board Market (Stock code: 688321.SH).
26 in Canada
40 in the United States
16 in Mexico
24 in Brazil
8 in South Africa
6 in Egypt
7 in Ukraine
32 in Europe
27 in Russia
322 in China
18 in India
26 in South Korea
29 in Japan
54 in Taiwan (China)
23 in Hong Kong
22 in Indonesia
6 in the Philippines
7 in Singapore
6 in the Malaysia
2 in the Vietnam
2 in the Thailand
26 in Australia
4 in New Zealand
75 PCT applications
2 in United Arab Emirates
2 in Bahrain
2 in Columbia
3 in Israel
2 in Jordan
2 in Saudi Arabia
